The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas

R. Abele, M. Clavel, P. Dodion, U. Bruntsch, S. Gundersen, J. Smyth, J. Renard, M. Van Glabbeke, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

The Early Clinical Trials Cooperative Group of the EORTC conducted several phase II studies with a pyrimidine analogue of deoxycytidine, 5-aza-2′-deoxycytidine (DAC). The drug was given as three consecutive 1 h i.v. infusions of 75 mg/m2, separated by intervals of 7 h; courses were repeated every 5 weeks. A total of 101 eligible patients were studied: 42 with colo-rectal adenocarcinoma, 27 with squamous cell carcinoma of the head and neck, 18 with malignant melanoma and 14 with renal cell carcinoma. Drug-induced toxicities consisted of moderate myelosuppression, and nausea and vomiting. One single partial remission was seen in a patient with malignant melanoma. DAC given in this dose and schedule is devoid of antitumour activity in adult patients with these refractory types of carcinomas.

Original languageEnglish (US)
Pages (from-to)1921-1924
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume23
Issue number12
DOIs
StatePublished - 1987
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this